Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 9;11(11):1275-1284.
doi: 10.1039/d0md00097c. eCollection 2020 Nov 18.

On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors

Affiliations

On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors

Vinicius Bonatto et al. RSC Med Chem. .

Abstract

The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. Hence, peptidomimetic cruzipain inhibitors having a reactive group (known as warhead) are subject to continuous studies to discover novel antichagasic compounds. Here, we evaluated how different warheads for a set of structurally similar related compounds could inhibit the activity of cruzipain and, ultimately, their trypanocidal effect. We first investigated in silico the intrinsic reactivity of these compounds by applying the Fukui index to correlate it with the enzymatic affinity. Then, we evaluated their potency against T. cruzi (Y and Tulahuen strains), which revealed the reversible cruzain inhibitor Neq0656 as a better trypanocidal agent (ECY.strain 50 = 0.1 μM; SI = 58.4) than the current drug benznidazole (ECY.strain 50 = 5.1 μM; SI > 19.6). We also measured the half-life time by HPLC analysis of three lead compounds in the presence of glutathione and cysteine to experimentally assess their intrinsic reactivity. Results clearly illustrated the reactivity trend for the warheads (azanitrile > aldehyde > nitrile), where the aldehyde displayed an intermediate intrinsic reactivity. Therefore, the aldehyde bearing peptidomimetic compounds should be subject for in-depth evaluation in the drug discovery process.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1. 2D schematic representation of the compounds presented in this study. Blue color depicts the difference in warhead structures.
Fig. 2
Fig. 2. Schematic representation of the warheads investigated using electrophilicity indices. Carbon (in blue) reacts with the thiolate nucleophile of cysteine. The Fukui index of electrophilicity was calculated for the carbon represented in blue.
Scheme 1
Scheme 1. Synthetic scheme for the synthesis of compounds Neq0646 and Neq0673. Conditions: (a) TFAA, NH4NO3, rt, 2 h; (b) 6 M HCl, SnCl2, 1.5 h, rt; (c) Trp-OH or Phe-OH, 1 M NaOH, 0 °C, 0.5 h; (d) EDC, HOBt, THF, rt, 18 h.
Fig. 3
Fig. 3. The putative linear equation and the coefficient of determination obtained through the linear correlation between ωc+ and pKiCz.

Similar articles

Cited by

  • Nitriles: an attractive approach to the development of covalent inhibitors.
    Bonatto V, Lameiro RF, Rocho FR, Lameira J, Leitão A, Montanari CA. Bonatto V, et al. RSC Med Chem. 2022 Nov 7;14(2):201-217. doi: 10.1039/d2md00204c. eCollection 2023 Feb 22. RSC Med Chem. 2022. PMID: 36846367 Free PMC article. Review.
  • Self-Masked Aldehyde Inhibitors: A Novel Strategy for Inhibiting Cysteine Proteases.
    Li L, Chenna BC, Yang KS, Cole TR, Goodall ZT, Giardini M, Moghadamchargari Z, Hernandez EA, Gomez J, Calvet CM, Bernatchez JA, Mellott DM, Zhu J, Rademacher A, Thomas D, Blankenship LR, Drelich A, Laganowsky A, Tseng CK, Liu WR, Wand AJ, Cruz-Reyes J, Siqueira-Neto JL, Meek TD. Li L, et al. J Med Chem. 2021 Aug 12;64(15):11267-11287. doi: 10.1021/acs.jmedchem.1c00628. Epub 2021 Jul 21. J Med Chem. 2021. PMID: 34288674 Free PMC article.

References

    1. Coura J. R. Viñas P. A. Nature. 2010;465:S6–S7. doi: 10.1038/nature09221. - DOI - PubMed
    1. Bern C. Kjos S. Yabsley M. J. Montgomery S. P. Clin. Microbiol. Rev. 2011;24:655–681. doi: 10.1128/CMR.00005-11. - DOI - PMC - PubMed
    1. Chatelain E. J. Biomol. Screening. 2015;20:22–35. doi: 10.1177/1087057114550585. - DOI - PubMed
    1. Jackson Y. Pinto A. Pett S. Trop. Med. Int. Health. 2014;19:212–218. doi: 10.1111/tmi.12235. - DOI - PubMed
    1. Pereira P. C. Navarro E. J. Venomous Anim. Toxins Incl. Trop. Dis. 2013;19:34. doi: 10.1186/1678-9199-19-34. - DOI - PMC - PubMed

LinkOut - more resources